SLC5A2 and heart failure: The Cardiovascular Events Associated With SGLT‐2 Inhibitors Versus Other Glucose‐Lowering Drugs study, a large international cohort spanning Singapore, Japan, Korea, Israel, Canada and Australia, found SGLT2i to be more cardioprotective than other glucose‐lowering medications, with stronger effects observed for heart failure in non‐Asian settings but no clear regional differences for other cardiovascular outcomes.28